Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Tamoxifen. Found 24 abstracts

no pagination
Chakraborty AK, Mehra R, Digiovanna MP. Co-targeting ER and HER family receptors induces apoptosis in HER2-normal or overexpressing breast cancer models. Anticancer research. 2015 Mar;35(3):1243-50.
Choi HJ, Lui A, Ogony J, Jan R, Sims PJ, Lewis-Wambi J. Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death. Breast Cancer Res. 2015 Jan 15;17:6.   PMCID: 4336497
Maximov PY, Myers CB, Curpan RF, Lewis-Wambi JS, Jordan VC. Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen. Journal of medicinal chemistry. 2010 Apr 22;53(8):3273-83.   PMCID: PMC2867604
Patel RR, Sengupta S, Kim HR, Klein-Szanto AJ, Pyle JR, Zhu F, Li T, Ross EA, Oseni S, Fargnoli J, Jordan VC. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Eur J Cancer. 2010 Jun;46(9):1537-53.   PMCID: PMC2927957
Jordan VC, Lewis-Wambi JS, Patel RR, Kim H, Ariazi EA. New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. Breast. 2009 Oct;18 Suppl 3:S10-7.   PMCID: PMC2867601
Jordan VC. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer. 2008 Jan;44(1):30-8.   PMCID: PMC2566958
Sengupta S, Jordan VC. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Advances in experimental medicine and biology. 2008 Jan;630:206-19.
Jordan VC. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids. 2007 Nov;72(13):829-42.
Jordan VC. Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point. Cancer Epidemiology, Biomarkers and Prevention. 2007 Nov;16(11):2207-9.
Jordan VC. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nature reviews Cancer. 2007 Jan;7(1):46-53.
O'Sullivan MJ, Morrow M. Ductal carcinoma in situ--current management. Surgical Clinics of North America. 2007 Apr;87(2):333-51.
Swaby RF, Sharma CG, Jordan VC. SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord. 2007 Sep;8(3):229-39.
Goldstein LJ. Controversies in adjuvant endocrine treatment of premenopausal women. Clinical Breast Cancer. 2006 Feb;6 Suppl 2:S36-40.
Gorin SS, Wang C, Raich P, Bowen DJ, Hay J. Decision making in cancer primary prevention and chemoprevention. Ann Behav Med. 2006 Dec;32(3):179-87.
Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. British journal of pharmacology. 2006 Jan;147 Suppl 1:S269-76.
Jordan VC, Knudson AG. Improvements in tumor targeting, survivorship, and chemoprevention pioneered by tamoxifen. A personal perspective. Oncology (Williston Park). 2006 May;20(6):553-62; discussion 567-8, 573, 577.
Freedman GM, Hanlon AL, Fowble BL, Anderson PR, Nicoloau N. Recursive partitioning identifies patients at high and low risk for ipsilateral tumor recurrence after breast-conserving surgery and radiation. J Clin Oncol. 2002 Oct;20(19):4015-21.
Torosian M, O'Shaughnessy J, Parker LM, Vogel C. Fulvestrant: clinical application of an estrogen receptor downregulator. Clinical therapeutics. 2002 Jan;24 Suppl A:A31-40.
Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug;20(15):3317-27.
Cianfrocca M, Goldstein LJ. Operable breast cancer. Current treatment options in oncology. 2001 Apr;2(2):157-67.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Tamoxifen

Female Breast Neoplasms Tamoxifen drug therapy therapeutic use Hormonal Antineoplastic Agents prevention & control Selective Estrogen Receptor Modulators metabolism administration & dosage pharmacology drug effects Raloxifene Human Adjuvant Chemotherapy Chemoprevention antagonists & inhibitors Estrogen Receptors Aromatase Inhibitors analogs & derivatives Adult Apoptosis Postmenopause Neoplasm Drug Resistance pathology Antineoplastic Combined Chemotherapy Protocols Anticarcinogenic Agents Tumor Cell Line Estrogen Antagonists history Signal Transduction Randomized Controlled Trials Disease-Free Survival Risk Factors mortality methods Biological Models Estrogen Receptor Modulators radiotherapy Cell Proliferation Aromatase 10540-29-1 (Tamoxifen) tu [Therapeutic Use] Segmental Mastectomy Immunohistochemistry Evidence-Based Medicine Premenopause su [Surgery] therapy Aged Estradiol 20th Century History chemistry surgery Drug Delivery Systems 21st Century History Hormonal) 0 (Antineoplastic Agents Combined Modality Therapy Survival Analysis Estrogens Rats 80 and over Aged Molecular Models Non-US Gov't Research Support Local Neoplasm Recurrence 0 (Aromatase Inhibitors) Binding Sites Clinical Trials as Topic X-Ray Crystallography Hormone Replacement Therapy Differentiation Antigens estrogen receptor (ER) dosage Survivors Nude Mice Follow-Up Studies Pyrroles Reverse Transcriptase Polymerase Chain Reaction genetics Protein Transport Primary Prevention Structure-Activity Relationship Treatment Outcome Stereoisomerism ErbB-2 Receptor Epidermal Growth Factor Receptor Neoplastic Gene Expression Regulation Her2 Cell Death Practice Guidelines Breast cancer STAT2 Transcription Factor Papillomavirus Infections Heterologous Transplantation Methotrexate Prognosis STAT1 Transcription Factor Fluorouracil Alanine Neoplasm Transplantation chemical synthesis Interferons Expert Testimony Biomedical Research Case Report Cell Cycle diagnosis analogs & Non-US Gov't Support enzymology Goserelin Fibroblast Growth Factor Receptor-Type 1 physiology Intracellular Space Drug Dose-Response Relationship Egfr Monoclonal Antibodies-Humanized Axilla Doxorubicin Vascular Endothelial Growth Factor Receptor-2 Forecasting Ethylenes Hormone-Dependent Neoplasms trends Carcinoma in Situ NIH Research Support-Extramural Portraits as Topic Endometrial Neoplasms Medical Oncology proliferation Lymph Node Excision Mice Adjuvant Radiotherapy Gw2974 Risk Assessment Cell Movement Enzyme Inhibitors Decision Making Sentinel Lymph Node Biopsy Osteoporosis Non-Steroidal Estrogens tamoxifen dt [Drug Therapy] Triazines analysis Gene Expression Gene Knockdown Techniques Neoplasms Neoadjuvant Therapy adverse effects
Last updated on Wednesday, March 04, 2020